Xixiang Li

 Assistant Professor

350 Shushanhu Road, Hefei, Anhui, 230031, P.R. China
Tel: +86-551-65593617
Email: lxx0420@hmfl.ac.cn

 

 

EDUCATION BACKGROUND

 

Sep.2002—Jul.2006
Anqing Normal University
Department of chemistry, School of Science

Sep.2006—Jun. 2008
Nanchang University
Department of chemistry, School of Science

 

WORK EXPERIENCE

 

Nov.2012-present, Assistant Professor, High Magnetic Field Laboratory, Chinese Academy of Sciences.

Jan.2009-2012. Oct, Pharmaron (Beijing) Technology Co. , Ltd.

 

PAPERS AND PATENTS

 

  1. Chen Hu#, Aoli Wang#, Hong Wu#, Ziping Qi#, Xixiang Li#, Xiao-E Yan#, Cheng Chen, Kailin Yu, Fengming Zou, Wenchao Wang, Wei Wang, Jiaxin Wu, Juan Liu, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, Qingsong Liu.* Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. Oncotarget 2017, 8(11): 18359-18372. doi: 10.18632/oncotarget.15443
  2. Xixiang Li#, Aoli Wang#, Kailin Yu#, Ziping Qi#, Cheng Chen, Wenchao Wang, Chen Hu, Hong Wu, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu*,Liu Qingsong*, Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia, J. Med. Chem, 2015, 58: 9625−9638.
  3. Hong Wu#, Aoli Wang#, Wei Zhang#, Beilei Wang#, Cheng Chen#,Wenchao Wang, Chen Hu, Zi Ye, Zheng Zhao, Li Wang, Xixiang Li, Kailin Yu,Juan Liu, Jiaxin Wu, Xiao-E Yan, Peng Zhao, Jinhua Wang, Chu Wang,Ellen L. Weisberg, Nathanael S. Gray, Cai-Hong Yun, Jing Liu*, Liang Chen*,Liu Qingsong*, Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells, Oncotarget, 2015 , 6(31): 31313-31322.
  4. Hong Wu#, Aoli Wang#, Ziping Qi#, Xixiang Li#, Cheng Chen#, Kailin Yu, Fengming Zou, Chen Hu, Wenchao Wang, Zheng Zhao, Jiaxin Wu, Juan Liu, Xiaochuan liu, Li Wang, Wei Wang, Shanchun Zhang, Richard M. Stone, Ilene A. Galinsky, James D. Griffin, David Weinstock, Alexandra Christodoulou, Huiping Wang, Yuanyuan Shen, Zhimin Zhai*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*， Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML，Leukemia, 2016，30(10): 2112-2116.
  5. Aoli Wang#, Xiao-E Yan#, Hong Wu#, Wenchao Wang#, Chen Hu, Cheng Chen, Zheng Zhao, Peng Zhao, Xixiang Li, Li Wang, Beilei Wang, Zi Ye, Jinhua Wang, Chu Wang, Wei Zhang, Nathanael S. Gray, Ellen L. Weisberg, Liang Chen, Jing Liu*,Cai-Hong Yun*, Qingsong Liu*，Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation，Oncotarget, 2016, 25;7(43): 69760-69769.
  6. 发明名称：FLT3激酶的新型抑制剂及其用途 发明人：刘静，刘青松，李希祥，王傲莉，吴宏，陈程，王文超，胡晨，赵铮，吴佳昕，刘娟，余凯琳，王伟，王黎，王蓓蕾 ; 专利受理号：201510028177.7
  7. 发明名称：一类新型的 EGFR 野生型和突变型的激酶抑制剂 发明人： 刘青松， 刘静， 李希祥，王傲莉，吴宏，余凯琳，胡晨，王文超，陈程，邹凤鸣，齐紫平，王黎，王蓓蕾 ; 专利受理号：201511030721.8
  8. 发明名称：FLT3激酶的新型抑制剂及其用途 发明人： 刘青松， 刘静， 李希祥， 王傲莉， 齐紫平，吴宏， 吴佳昕，王文超，胡晨，陈程， 王黎，王蓓蕾; 专利受理号：201610409235.5
  9. FLT3 kinase new inhibitors and its application, Liu, Qingsong; Liu Jing;Li Xixiang;Wang Aoli; Wu Hong; Chen Cheng;Wang Wenchao; Hu Chen; Zhao Zheng; Wu Jiaxin; Liu Juan;Yu Kailin; Wang Wei; Wang Li; Wang Beilei. (2015); PCT/CN2015/086318
  10. Ibrutinib is sensitive to FLT3-ITD dependent AML, Liu, Qingsong; Liu Jing; Wu Hong; Hu Chen; Wang Aoli; Wang Wenchao; Chen Cheng; Li Xixiang; Zhao Zheng; Wang Li; Wang Beilei.(2014); PCT/CN2014/091375
  11. FLT3 kinase new inhibitors and its application, Liu, Qingsong; Liu Jing;Li Xixiang; Wang Aoli; Wu Hong; Chen Cheng;Wang Wenchao; Hu Chen; Zhao Zheng; Wu Jiaxin; Liu Juan;Yu Kailin; Wang Wei; Wang Li; Wang Beilei. (2015);PCT/CN2015/086318